Clinical Trials Directory

Trials / Completed

CompletedNCT01783301

Anti-Mullerian Hormone (AMH) Versus Antral Follicle Count (AFC) Guided rFSH Dosing Study

A Phase IV, Open-label 2 Arm Trial to Compare the Efficacy and Safety of a Pre-defined Dose of GONAL-f® Based on Antral Follicle Count [Follicles ≥2mm - <11mm]), or AMH for Ovarian Stimulation in Subjects Undergoing Assisted Reproductive Technology (ART) Treatment.

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
348 (actual)
Sponsor
Vietnam National University · Academic / Other
Sex
Female
Age
20 Years – 45 Years
Healthy volunteers
Not accepted

Summary

The overall objectives of this trial are to: * To explore the efficacy and safety of using either antral follicle count (AFC) or anti-Mullerian hormone (AMH) to guide the starting dose of GONAL-f® in ovarian stimulation for Assisted Reproductive Technology (ART). * To assess the differences in both ovarian response and clinical pregnancy rate between subjects with different AFC and AMH levels undergoing ART.

Detailed description

Trial design This trial is a prospective, Phase IV 2 arm trial exploring the efficacy and safety of using either AFC or AMH to guide the starting GONAL-f® dose for the stimulation treatment of subjects undergoing ART. Throughout the trial period and before the start of a routine ART cycle, investigators will propose the trial to their potential subjects. All subjects who agree to participate in the trial must sign a consent form, irrespective of whether or not they ultimately agree to have their dose determined by the study protocol. Eligible subjects will be randomised in blocks of 4 at each site via a computer generated random number list to either the AFC guided arm (control) or the AMH guided arm (treatment). The starting doses of GONAL-f® for each arm will be based on the study algorithms, using AFC or AMH guidance. The investigator will then enter initiate ovarian stimulation with an individualised GONAL-f® dose for that specific subject. This will be maintained for the first 5 days of stimulation after which the dose can be modified based on investigator decision and in accordance with the site's routine clinical practice. Trial Population Female partners of infertile couples requiring Assisted Reproductive Technology (ART) treatment. Data Analysis and Statistics The primary end-point proportion of patients with desired number of retrieved oocytes (8-12) will be compared between the 2 arms using the chi -square test. The null hypothesis will be that there is no difference between the 2 arms in primary end-point, with the p level set at p=0.05. The secondary end-points will also be compared between the 2 arms using either the Student's t test or anova test.

Conditions

Interventions

TypeNameDescription
DRUGFSH

Timeline

Start date
2011-10-01
Primary completion
2012-08-01
Completion
2012-12-01
First posted
2013-02-04
Last updated
2013-02-04

Locations

1 site across 1 country: Vietnam

Source: ClinicalTrials.gov record NCT01783301. Inclusion in this directory is not an endorsement.